Icecure's prosense® featured at sir 2022 annual meeting in breast cancer cryoablation categorical course

Strong interest in prosense from potential customers and distributors spurred by categorical course and shanghai medtronic deal caesarea, israel , june 15, 2022 /prnewswire/ -- icecure medical ltd. (nasdaq: iccm) (tase: iccm) ("icecure" or the "company"), developer of minimally-invasive cryoablation technology, the prosense® system that destroys tumors by freezing as an alternative to surgical tumor removal, today announced prosense was featured in a categorical course titled "cryoablation for the treatment of breast cancer: breast interventions for the interventionalist" on tuesday, june 14, 2022 at the society of interventional radiology (sir) annual scientific meeting in boston ("sir 2022 conference").
MDT Ratings Summary
MDT Quant Ranking